Cohen et al (11), (12) | 285 | Facial wrinkles | Artecoll v. collagen | Facial fold assessment scale (0–5), 6 mo | Photos, 3 investigators | Inspection, treating investigator |
Oesterle et al. (13) | 221 | Angina pectoris | Laser (TMR) v. medication only | CCSA class (I–IV), 12 mo | Interview, assistant; CCSA, cardiologist | Interview and CCSA, cardiologist |
Powell et al. (14) | 22 | Turbinate hypertrophy | Radiofrequency reduction v. sham | Nasal obstruction (10-cm VAS), 4 wk | Nasal examination (rhinoscopy) | Nasal examination (rhinoscopy) |
Burkhoff et al. (15) | 182 | Angina pectoris | Laser (TMR) v. medication only | CCSA class (I–IV), 12 mo | Interview; assistant; CCSA, cardiologist | Interview and CCSA, cardiologist |
Wedekind et al. (16) | 75 | Panic disorder | Aerobic exercise v. relaxation | PAS (0–52), 8 wk | Clinical assessment, rater | Clinical assessment, rater |
Weaver et al. (17) | 255 | Parkinson disease | Deep brain stimulation v. standard care | UPDRS III (0–108), 6 mo | Examination, neurologist | Examination, neurologist |
Noseworthy et al. (18) | 168 | Multiple sclerosis | Plasma exchange and cyclophosphamide v. placebo | EDSS (0–10), 12 mo | Examination, neurologist | Examination, neurologist |
Narins et al. (19) | 118 | Facial wrinkles | Hyaluronic acid v. collagen | Wrinkle severity rating scale (0–4), 12 wk | Inspection, evaluator | Inspection, treating investigator |
Ulm et al. (20) | 49 | Parkinson disease | Cabergolin v. pergolid | UPDRS III (0–108), 8 wk | Video, investigator | Examination, treating investigator |
Meltzer et al. (21), (22) | 980 | Suicide risk | Olanzapine v. Clozapine | CGI-SS, 24 mo | Clinical assessment, psychiatrists | Clinical assessment, psychiatrist |
Miller et al. (23) | 50 | Nasal wound | MeroGel v. Merocel dressing | Synechia (0–3), last follow-up | Endoscopic image, 3 investigators | Live endoscopy, clinician |
Taber et al. (24) | 26 | RSV infection | Ribavirin aerosol v. placebo | Illness severity score (0–3), day 1 | Clinical assessment, clinician | Clinical assessment, clinician |
US FDA (25) | 261 | Facial wrinkles | Hylaform v. Zyplast | Severity grading scale (0–5), week 12 | Photos, panel | Live inspection, treating investigator |
Landsman et al. (26) | 36 | Onychomycosis | Light therapy v. sham light | CAS* (0–3), day 180 | Photos, expert panel | Live inspection, treating physicians |
Iglesia et al. (27) | 65 | Vaginal prolapse | Polypropylene mesh v. standard | POP-Q (0-IV), 3 mo | Examination, practitioner (e.g., nurse, fellow) | Examination, surgeon |
Reddihough et al. (28) | 61 | Cerebral palsy | Botulinum toxin A v. physiotherapy | GMFM (0–264), 6 mo | Video, physiotherapist | Examination,† physiotherapist |